Abstract 2361MO
Background
In MIBC standard staging with CT imaging is critical for making treatment decisions about neoadjuvant chemotherapy (NAC), and local treatment with either radical cystectomy (RC) or chemoradiation. However, CT imaging can often underestimate disease extent. The aim of this randomized study was to determine if adding 18F-FDG PET/CT (PET) to baseline CT, changes treatment received.
Methods
Newly diagnosed MIBC pts (T2a-T4, N0-3, M0) without metastases on baseline CT, and predominant urothelial histology, were allocated 2:1 to PET or no further imaging. Enrollment occurred 05/16-11/21 at 6 Ontario centers. At the time of analysis, median duration of follow-up was 2 years. Primary outcome was proportion of pts not receiving expected treatment and secondary outcomes were disease-free survival (DFS) and overall survival (OS).
Results
Of 292 pts, 194 were randomized to PET and 98 to no PET. In the PET and no PET arms respectively: median age was 70 (43-93) and 68 (42-89); T2: 77% and 77%; node negative 88% and 87%; planned RC 66% and 69%; and planned NAC 70% and 64%. On PET, primary bladder tumor was seen in 86 (47%) pts, positive pelvic lymph nodes in 37 (20%), distant nodes in 32 (18%) and distant metastases in 13 (7%). By ITT analysis, 166 (86%) PET pts received expected treatment, 21 (11%) did not and 7 (4%) withdrew/died prior to treatment. In the no PET arm, 90 (92%) received expected treatment, 4 (4%) did not, and 4 (4%) withdrew/died prior to treatment. More PET pts were deemed palliative 18 (9.3%) vs 3 (3.1%). Notably >60% in both arms received NAC. PET pts were more likely to have a change in treatment, odds ratio 2.89 (95% CI 0.96-8.74, p=0.06) compared to CT alone. No statistically significant difference was observed between arms for DFS (HR=0.78, 95% CI 0.55-1.12) or OS (HR=1.02, 95% CI 0.66-1.56).
Conclusions
In this large randomized study, there was a trend towards a change in management in pts having a PET, but this did not reach statistical significance. This trial provides new insights into the clinical utility of PET-CT in MIBC.
Clinical trial identification
NCT02462239.
Editorial acknowledgement
Legal entity responsible for the study
Ontario Clinical Oncology Group (OCOG).
Funding
Cancer Care Ontario.
Disclosure
S. Sridhar: Financial Interests, Personal, Advisory Board: Astellas, AstraZeneca, Bayer, BMS, EMD Serono, Pfizer, Seagen, Gilead; Financial Interests, Institutional, Research Grant, Unrestricted Research grant to institution for developing a database: Seagen. R. Breau: Financial Interests, Personal, Advisory Board: Knight Therapeutics, Ferring, TerSera, Tolmar Pharmaceuticals, Merck, Astellas, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
2362MO - Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select FGFR alterations (FGFRalt): Subgroups from the phase III THOR study
Presenter: Yohann Loriot
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 2361MO and 2362MO
Presenter: Patrizia Giannatempo
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
2363MO - A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2)
Presenter: Bernadett Szabados
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
2364MO - Durvalumab (D) +/- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial
Presenter: Constance Thibault
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
2365MO - Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)
Presenter: Srikala Sridhar
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 2363MO, 2364MO and 2365MO
Presenter: Ursula Vogl
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
LBA104 - First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)
Presenter: Antoni Vilaseca
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA105 - Results from SunRISe-1 in patients (Pts) with bacillus Calmette–Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy
Presenter: Andrea Necchi
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA104 and LBA105
Presenter: Joost Boormans
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
1883MO - MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)
Presenter: Martin Voss
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast